Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 7710 results

  1. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  2. Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  3. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)

    Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

  4. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

    Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.

  5. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

  6. Faricimab for treating diabetic macular oedema (TA799)

    Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

  7. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

  8. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

  9. Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.

  10. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

  11. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

  12. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

  13. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.

  14. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) (TA839)

    NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.

    Sections for TA839

  15. Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) (TA840)

    NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.

    Sections for TA840